Full of sound and fury, signifying nothing
Published October 25, 2024
Novo Nordisk tried to convince the FDA that semaglutide injections are difficult to compound. (Spoiler: They aren't.)
APC News
Video: APC on Scripps
Published October 18, 2024
APC CEO Scott Brunner appeared on the Scripps News show “America On The Docket,” talking about the “brewing legal battle” over compounded tirzepatide and semaglutide.
BREAKING: FDA allows renewed compounding of tirzepatide copies — for now
Published October 18, 2024
In a win for continued patient access to compounded versions of Eli Lilly’s Mounjaro and Zepbound, FDA clarified today that pharmacies may continue to prepare copies of those FDA-approved drugs, at least for now.
FDA issues IV fluids emergency guidance
Published October 17, 2024
The FDA has published emergency guidance that empowers pharmacies to help address the nationwide IV solutions shortage.
The Journey to Earning the CPhT-Adv Certification from PTCB
Published October 17, 2024
Earning the Advanced Certified Pharmacy Technician Certification from the Pharmacy Technician Certification Board is a great way to boost your professional skills and career opportunities.
Technicians: Professional Development through Mentorship
Published October 17, 2024
Mentors play a crucial role in career advancement by offering guidance, encouragement, advocacy, and networking potential. Identifying the right mentor within your industry is essential.
FDA reconsiders on tirzepatide, big questions remain
Published October 15, 2024
After a court order, the FDA agreed to reconsider taking tirzepatide off the shortage list.
Reporter briefing: Patient impacts of tirzepatide shortage resolution
Published October 11, 2024
APC's media briefing shared compounders' first-hand stories with more than 30 reporters from across the country.
Be sure your marketing follows these best practices
Published October 11, 2024
APC's new guide will help you stay on the right side of laws and regs.
A fake survey from a pharma-funded organization
Published October 11, 2024
What the Partnership for Safe Medicines released "Ain't a legitimate survey."
Lots of letters
Published October 11, 2024
On the compounding front, the FDA’s inbox is getting quite a workout lately.
Slick new dosing pen for compounders
Published October 11, 2024
Love Lifesciences’ UniPen injector pen is not only a Very Big Deal, it's available at a discount for APC PFM members.
FDA says tirzepatide shortage “resolved”
Published October 2, 2024
As of this afternoon, the FDA Drug Shortage List is showing that the shortage of tirzepatide injection is “resolved.” Pharmacies must immediately cease preparing and dispensing compounded copies of Mounjaro and Zepbound.
Get yer law and patient safety CE here
Published October 2, 2024
We've made the most popular segment of our 15-hour legal course into a standalone 3-hour, on-demand CE program.
Vet compounders: How has GFI 256 changed things?
Published October 2, 2024
Simply put, we want to know if you’ve been affected by recent FDA guidance on veterinary compounding.
Being a PFM just got better
Published September 27, 2024
APC is launching five new benefits for our Pharmacy-Facility members to help you and your business prosper.
Thompson elected, Browning appointed
Published September 27, 2024
Two changes to boards of directors were made last week.
HIPAA, schmipaa — Lilly is at it again
Published September 20, 2024
Now Eli Lilly is trying to "convince" people who have used compounded versions of tirzepatide to share their confidential medical records with the company.
Settlement reached in Evexias suit against FDA
Published September 20, 2024
A settlement has been reached in a lawsuit brought by Evexias et al against FDA over the agency's 2023 addition of a number of substances to Category 2 of the 503A bulks list.
Rochefort receives Malmberg Award
Published September 20, 2024
David Rochefort of Revelation Pharma is this year's recipient of the George and Lucy Malmberg Compounding Advocacy Champion award — APC’s highest honor.
For they’re jolly good Fellows*
Published September 20, 2024
This year’s CCH featured the induction of seven new APC fellows.
Be fruitful and multiply … our messaging, that is
Published September 13, 2024
Even if you didn't attend Compounders on Capitol Hill, you can multiply the effect of those Hill visits.
APC supports upcoming DEA guidance on constructive transfer
Published September 13, 2024
Some good news: DEA is set to issue much-needed new guidance on constructive transfer.
503Bs: FDA has questions, and so do we (do you?)
Published September 13, 2024
FDA has requested comments on the challenges and opportunities faced by compounding outsourcing facilities.
Meet our compounding defenders, guardians and champions (Oh my!)
Published September 13, 2024
Here’s a big thank you to our Package Deal investors.
PCAC to discuss 503A bulks list substances
Published September 6, 2024
FDA’s Pharmacy Compounding Advisory Committee has announced that it will hold two meetings (!) between now and year-end to consider recommending several bulk drug substances to the 503A Bulks List.
Welcome, new PFMs!
Published September 6, 2024
We’ve added 31 Pharmacy-Facility Members since February!
Let’s talk about that Lilly announcement
Published August 30, 2024
There’s been plenty of coverage of Eli Lilly’s announcement this week that it will sell vials of Zepbound directly to consumers at a discount. But the company seems to have left out a few important caveats.
Our response to the op-ed in The Hill
Published August 30, 2024
The Hill published an editorial by Dr. Kenneth McCall titled “Fake, unsafe weight-loss drugs are a worsening public health dilemma” in which he makes unfounded claims about pharmacy compounding. Here’s the response from our CEO.
